May 18, 2016 / 11:17 AM / in a year

BRIEF-Health Canada authorizes ProMetic to proceed with PBI-4050 clinical trial

May 18 (Reuters) - ProMetic Life Sciences Inc Says To Commence Clinical Trial Of Its Orally Active Anti

* Says to commence clinical trial of its orally active anti-fibrotic lead drug candidate, PBI-4050

* Phase 2 clinical trial of PBI-4050 to commence in Q2 2016 as planned

* Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below